Biofluid proteases profiling in diabetes mellitus

Adv Clin Chem. 2015:69:161-207. doi: 10.1016/bs.acc.2014.12.004. Epub 2015 Feb 7.

Abstract

The investigation of protease relevance in biologic systems beyond catabolism of proteins and peptides to amino acids has stimulated interest as to their role in the pathogenesis of several disorders including diabetes mellitus (DM). Evaluation of proteases and the assessment of their activity in biofluids are fundamental to elucidate these proteolytic systems in DM and its related complications. In contrast to traditional immunoassay or substrate based approaches that targeted specific proteases and their inhibitors, the field of degradomics has provided a comprehensive approach to study these enzymes. Although the degradome contains over 500 proteases, very few have been associated with DM and its micro- and macrovascular complications. In this paper, we review these proteases and their respective inhibitors with emphasis on DM. It is likely that future research will expand these initial studies and look to develop high throughput automated technologies to identify and characterize biofluid proteases of diagnostic and prognostic value in other pathologies.

Keywords: Biofluids; Diabetes mellitus; Inhibitors; Proteases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers / blood*
  • Chemistry, Clinical / methods*
  • Diabetes Complications / blood
  • Diabetes Complications / enzymology
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / enzymology*
  • Humans
  • Molecular Targeted Therapy
  • Peptide Hydrolases / analysis
  • Peptide Hydrolases / blood*
  • Protease Inhibitors / pharmacology
  • Tissue Inhibitor of Metalloproteinases / blood

Substances

  • Biomarkers
  • Protease Inhibitors
  • Tissue Inhibitor of Metalloproteinases
  • Peptide Hydrolases